Kestra Medical Technologies CEO Brian Webster sells $692,214 in stock

Brian Daniel Webster, President and Chief Executive Officer of Kestra Medical Technologies, Ltd. (KMTS), recently sold a total of $692,214 worth of company common shares across three separate transactions. The sales occurred between July 30 and August 3, 2026, with prices ranging from $22.6039 to $23.9244 per share. Mr. Webster is also a director of the company. The stock has since climbed to $28.02, trading near its 52-week high of $30.00 following a remarkable 75% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value—making it one to watch on the Most Overvalued list.

On July 30, Mr. Webster disposed of 7,857 common shares at a weighted average price of $22.7225. Individual sales on this date ranged from $22.2524 to $23.1700. The following day, July 31, saw the sale of an additional 8,948 common shares at a weighted average price of $22.6039, with prices for individual sales between $22.0577 and $22.9200. The final reported transaction on August 3 involved the sale of 13,017 common shares at a weighted average price of $23.9244, with individual sales occurring between $23.6400 and $24.1100.

These transactions were nondiscretionary sales of shares, executed to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. Following these reported sales, Mr. Webster beneficially owns 527,115 common shares of Kestra Medical Technologies, Ltd. (KMTS). For deeper insights into KMTS’s valuation and performance, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.

In other recent news, Kestra Medical Technologies reported a notable 66% increase in revenue for its fiscal fourth quarter of 2026, reaching $28.6 million, surpassing the consensus estimate of $26.5 million. Despite the revenue growth, the company reported a larger-than-expected loss per share of $0.67, missing Wall Street’s forecast of a $0.58 loss. Stifel reiterated its Buy rating on Kestra Medical, setting a price target of $30.00, following the strong revenue performance. Wolfe Research also raised its price target to $30.00 from $29.00, citing the company’s execution exceeding expectations. Meanwhile, JPMorgan initiated coverage on Kestra Medical with an Overweight rating and a price target of $30.00, highlighting the potential of its ASSURE wearable cardioverter-defibrillator. Oppenheimer initiated coverage with a Perform rating, acknowledging the large addressable market and ongoing market share gains against the incumbent. These developments reflect Kestra Medical’s continued growth and strategic positioning in the wearable medical device market.